Related Experiment Video
Updated: May 28, 2025
08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
8.8K
Homoharringtonine: mechanisms, clinical applications and research progress
Wen Wang1, Lan He2,3, Ting Lin1,2,3
1Graduate School, Hunan University of Chinese Medicine, Changsha, China.
Frontiers in Oncology
|February 14, 2025
Summary
Homoharringtonine (HHT) shows promise in treating blood cancers by inducing apoptosis and inhibiting cell growth. Research is exploring drug delivery systems to improve HHT
Area of Science:
- Pharmacology
- Natural Products Chemistry
- Oncology
Background:
- Homoharringtonine (HHT) is a natural alkaloid with demonstrated efficacy in hematological malignancies.
- HHT exhibits anticancer properties by inducing apoptosis, cell cycle arrest, and inhibiting cell migration.
- HHT also possesses immunomodulatory, antiviral, anti-fibrotic, and neuroprotective activities.
Purpose of the Study:
- To systematically review the pharmacological mechanisms of Homoharringtonine (HHT).
- To explore HHT's efficacy in treating hematological malignancies.
- To discuss strategies for overcoming HHT's limitations, such as low bioavailability and side effects.
Main Methods:
- Systematic literature review of Homoharringtonine's pharmacological actions.
- Analysis of clinical trial data for HHT in hematological malignancies.
- Review of novel drug delivery systems (nanoparticles, liposomes) and chemical modifications to enhance HHT bioavailability and targeting.
Main Results:
- Homoharringtonine effectively treats hematological malignancies like acute myeloid leukemia and chronic myeloid leukemia.
- Low bioavailability and potential side effects are key challenges for HHT clinical use.
- Advanced drug delivery systems and chemical modifications significantly improve HHT's in vivo bioavailability, targeting, and reduce toxicity.
Conclusions:
- Homoharringtonine is a potent natural alkaloid with broad therapeutic potential in oncology and other fields.
- Strategies to enhance HHT bioavailability and delivery are crucial for its wider clinical application.
- Combination therapies involving HHT offer promising avenues for improved cancer treatment outcomes.
Related Concept Videos
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:25Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
926
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
926
01:21Antipsychotic Drugs: Typical and Atypical Agents
149
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
149
01:23Antidepressant Drugs: MAOIs and Other Agents
181
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
181